Assertio Reports Mixed 2025 Results Amid Rolvedon Transition
Event summary
- Rolvedon sales dropped to $0.4M in Q4 2025 from $15.4M a year earlier due to distribution transition.
- Full-year Rolvedon sales rose 13% to $68.2M, driven by inventory sell-in and prior-period adjustments.
- Sympazan sales grew 9% YoY in Q4, while Indocin faced generic competition pressure.
- Adjusted EBITDA swung to a loss of $4.1M in Q4 from a profit of $3.4M a year earlier.
- 2026 guidance projects $110M–$125M in net product sales and $28M–$40M in adjusted EBITDA.
The big picture
Assertio's strategic pivot away from specialty product acquisitions reflects broader industry consolidation trends. The company is betting on its commercial infrastructure and market access capabilities to drive oncology portfolio growth, but faces near-term execution risks during Rolvedon's distribution transition. Full-year 2025 results highlight the challenges of balancing revenue stability with long-term strategic repositioning.
What we're watching
- Product Transition Risk
- How the Rolvedon distribution transition will impact Q2 2026 sales under the new label.
- Oncology Expansion
- Whether Assertio can successfully build a differentiated oncology portfolio beyond Rolvedon.
- Cost Management
- The pace at which SG&A reductions will offset revenue pressures from generic competition.
Related topics